ASSURE Wearable Cardioverter Defibrillator (WCD) System
Kestra Medical Technologies, Inc. · Decision date Sep 28, 2026
What did the FDA decide?
The FDA record for P200037/S021 identifies a 30-day notice for the ASSURE Wearable Cardioverter Defibrillator (WCD) System, product code MVK, submitted by Kestra Medical Technologies, Inc. The stated purpose is an updated workflow for the post-wear data transfer process, filed under the supplement reason process change affecting a manufacturer, sterilizer, packager or supplier.
The S021 suffix ties this filing to the original PMA P200037, but it is a supplement, not a new approval of the whole system. The notice describes a manufacturing and process update only; it does not establish safety or clinical effectiveness. The record does not specify which workflow steps, data pathways or components changed, leaving that detail absent.
FDA approval order statement
an updated workflow for the post-wear data transfer process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P200037/S021
- Regulatory pathway
- PMA supplement
- Applicant
- Kestra Medical Technologies, Inc.
- Product code
- MVK
- Decision code
- OK30
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Wearable automated external defibrillator.
- Applicant
- Kestra Medical Technologies, Inc.
- Product code
- MVK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200037 · Original PMA
ASSURE Wearable Cardioverter Defibrillator (WCD) System
P200037/S021 received
Application receipt date recorded by FDA.
P200037/S021 · FDA decision
30-Day Notice
P200037/S022 · Related supplement
ASSURE Wearable Cardioverter Defibrillator (WCD) System
Timeline entries are records held by MedtechLedger for P200037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Kestra Medical Technologies, Inc. | PMA approval | Jul 27, 2021 | FDA | |
| Kestra Medical Technologies, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code MVK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LifeVest Wearable DefibrillatorP010030/S205 | Zoll Manufacturing Corporation | PMA supplement | Oct 6, 2026 | FDA |
LifeVest Wearable DefibrillatorP010030/S204 | Zoll Manufacturing Corporation | PMA supplement | Oct 5, 2026 | FDA |
LifeVest Wearable DefibrillatorP010030/S203 | Zoll Manufacturing Corporation | PMA supplement | Sep 29, 2026 | FDA |
LifeVest Wearable DefibrillatorP010030/S201 | Zoll Manufacturing Corporation | PMA supplement | Sep 9, 2026 | FDA |
| Zoll Manufacturing Corporation | PMA approval | Dec 18, 2001 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kestra Medical Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3933 Lake Washington Blvd. NE, Suite 200, Kirkland, WA, 98033
Sources and methodology
- Original FDA record: P200037/S021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




